Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

References

• Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10:eaat7807. doi:10.1126/scitranslmed.aat7807.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–10. doi:10.1126/science.aaa8172.
   PubMed Web of Science ®Google Scholar
• Vitale I, Sistigu A, Manic G, Rudqvist N-P, Trajanoski Z, Galluzzi L. Mutational and antigenic landscape in tumor progression and cancer immunotherapy. Trends Cell Biol. 2019;29:396–416. doi:10.1016/j.tcb.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–214. doi:10.1016/j.cell.2015.03.030.
   PubMed Web of Science ®Google Scholar
• Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020;17:137–150. doi:10.1038/s41585-020-0282-3.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20:75–76. doi:10.1038/s41577-020-0275-8.
   PubMed Web of Science ®Google Scholar
• Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol. 2020. doi:10.1038/s41577-020-0300-y.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ruiz ME, Vitale I, Harrington KJ, Melero I, Galluzzi L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol. 2020;21:120–134. doi:10.1038/s41590-019-0561-4.
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25–39. doi:10.1038/s41577-019-0218-4.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164:1233–1247. doi:10.1016/j.cell.2016.01.049.
   PubMed Web of Science ®Google Scholar
• June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med. 2017;23:540–547. doi:10.1038/nm.4321.
   PubMed Web of Science ®Google Scholar
• Esfahani K, Calabrese L. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020. doi:10.1038/s41571-020-0352-8.
   Web of Science ®Google Scholar
• Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38. doi:10.1038/s41572-020-0160-6.
   PubMed Web of Science ®Google Scholar
• Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17:474–502. doi:10.1038/s41569-020-0348-1.
   PubMed Web of Science ®Google Scholar
• Yu PP, Eton O, Garrison LP. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. J Immunother Cancer. 2019;7:235. doi:10.1186/s40425-019-0707-9.
   PubMed Web of Science ®Google Scholar
• Chu JN, Choi J, Ostvar S, Torchia JA, Reynolds KL, Tramontano A, Gainor JF, Chung DC, Clark JW, Hur C, et al. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Cancer. 2019;125:278–289. doi:10.1002/cncr.31795.
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95–106. doi:10.1038/nrc2051.
   PubMed Web of Science ®Google Scholar
• Levesque S, Le Naour J, Pietrocola F, Paillet J, Kremer M, Castoldi F, Baracco EE, Wang Y, Vacchelli E, Stoll G, et al. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. Oncoimmunology. 2019;8:e1657375. doi:10.1080/2162402X.2019.1657375.
   PubMed Web of Science ®Google Scholar
• Ahern E, Harjunpää H, O’Donnell JS, Allen S, Dougall WC, Teng MWL, Smyth MJ. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. Oncoimmunology. 2018;7:e1431088. doi:10.1080/2162402X.2018.1431088.
   PubMed Web of Science ®Google Scholar
• Medler T, Patel JM, Alice A, Baird JR, Hu HM, Gough MJ. Activating the nucleic acid-sensing machinery for anticancer immunity. Int Rev Cell Mol Biol. 2019;344:173–214. doi:10.1016/bs.ircmb.2018.08.006.
   PubMed Web of Science ®Google Scholar
• Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: toll-like receptor agonists in cancer immunotherapy. Oncoimmunology. 2018;7:e1526250. doi:10.1080/2162402X.2018.1526250.
   PubMed Web of Science ®Google Scholar
• Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I. An RNA toolbox for cancer immunotherapy. Nat Rev Drug Discov. 2018;17:751–767. doi:10.1038/nrd.2018.132.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Hoffmann JA, Galluzzi L. Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2019;18:845–867. doi:10.1038/s41573-019-0043-2.
   PubMed Web of Science ®Google Scholar
• Khodarev NN. Intracellular RNA sensing in mammalian cells: role in stress response and cancer therapies. Int Rev Cell Mol Biol. 2019;344:31–89. doi:10.1016/bs.ircmb.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Heil M, Vega-Munoz I. Nucleic acid sensing in mammals and plants: facts and caveats. Int Rev Cell Mol Biol. 2019;345:225–285. doi:10.1016/bs.ircmb.2018.10.003.
   PubMed Web of Science ®Google Scholar
• Guha M. Anticancer TLR agonists on the ropes. Nat Rev Drug Discov. 2012;11:503–505. doi:10.1038/nrd3775.
   PubMed Web of Science ®Google Scholar
• Vascotto F, Petschenka J, Walzer KC, Vormehr M, Brkic M, Strobl S, Rösemann R, Diken M, Kreiter S, Türeci Ö, et al. Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. Oncoimmunology. 2019;8:1601480. doi:10.1080/2162402X.2019.1601480.
   PubMed Web of Science ®Google Scholar
• Hennessy EJ, Parker AE, O’Neill LA. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9:293–307. doi:10.1038/nrd3203.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7–24. doi:10.1038/s41577-019-0210-z.
   PubMed Web of Science ®Google Scholar
• Sprooten J, Agostinis P, Garg AD. Type I interferons and dendritic cells in cancer immunotherapy. Int Rev Cell Mol Biol. 2019;348:217–262. doi:10.1016/bs.ircmb.2019.06.001.
   PubMed Web of Science ®Google Scholar
• Lee YS, Radford KJ. The role of dendritic cells in cancer. Int Rev Cell Mol Biol. 2019;348:123–178. doi:10.1016/bs.ircmb.2019.07.006.
   PubMed Web of Science ®Google Scholar
• Blander JM. Regulation of the cell biology of antigen cross-presentation. Annu Rev Immunol. 2018;36:717–753. doi:10.1146/annurev-immunol-041015-055523.
   PubMed Web of Science ®Google Scholar
• Cruz FM, Colbert JD, Merino E, Kriegsman BA, Rock KL. The biology and underlying mechanisms of cross-presentation of exogenous antigens on MHC-I molecules. Annu Rev Immunol. 2017;35:149–176. doi:10.1146/annurev-immunol-041015-055254.
   PubMed Web of Science ®Google Scholar
• Unanue ER, Turk V, Neefjes J. Variations in MHC class II antigen processing and presentation in health and disease. Annu Rev Immunol. 2016;34:265–297. doi:10.1146/annurev-immunol-041015-055420.
   PubMed Web of Science ®Google Scholar
• Kotsias F, Cebrian I, Alloatti A. Antigen processing and presentation. Int Rev Cell Mol Biol. 2019;348:69–121. doi:10.1016/bs.ircmb.2019.07.005.
   PubMed Web of Science ®Google Scholar
• Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L, et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology. 2020;9:1703449. doi:10.1080/2162402X.2019.1703449.
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–305. doi:10.1126/science.1071059.
   PubMed Web of Science ®Google Scholar
• Lupfer CR, Rippee-Brooks MD, Anand PK. Common differences: the ability of inflammasomes to distinguish between self and pathogen nucleic acids during infection. Int Rev Cell Mol Biol. 2019;344:139–172. doi:10.1016/bs.ircmb.2018.10.001.
   PubMed Web of Science ®Google Scholar
• Tan X, Sun L, Chen J, Chen ZJ. Detection of microbial infections through innate immune sensing of nucleic acids. Annu Rev Microbiol. 2018;72:447–478. doi:10.1146/annurev-micro-102215-095605.
   PubMed Web of Science ®Google Scholar
• Chow KT, Gale M Jr., Loo YM. RIG-I and other RNA sensors in antiviral immunity. Annu Rev Immunol. 2018;36:667–694. doi:10.1146/annurev-immunol-042617-053309.
   PubMed Web of Science ®Google Scholar
• Burgueno JF, Abreu MT. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat Rev Gastroenterol Hepatol. 2020;17:263–278. doi:10.1038/s41575-019-0261-4.
   PubMed Web of Science ®Google Scholar
• Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95–112. doi:10.1038/s41577-019-0215-7.
   PubMed Web of Science ®Google Scholar
• Choi HW, Klessig DF. DAMPs, MAMPs, and NAMPs in plant innate immunity. BMC Plant Biol. 2016;16:232. doi:10.1186/s12870-016-0921-2.
   PubMed Web of Science ®Google Scholar
• Versluys M, Tarkowski LP, Van den Ende W. Fructans AS DAMPs or MAMPs: evolutionary prospects, cross-tolerance, and multistress resistance potential. Front Plant Sci. 2016;7:2061. doi:10.3389/fpls.2016.02061.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405–414. doi:10.1038/nri3845.
   PubMed Web of Science ®Google Scholar
• McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15:87–103. doi:10.1038/nri3787.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8. doi:10.1136/jitc-2019-000337.
   Web of Science ®Google Scholar
• Pouwels SD, Heijink IH, Ten Hacken NH, Vandenabeele P, Krysko DV, Nawijn MC, van Oosterhout AJ. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol. 2014;7:215–226. doi:10.1038/mi.2013.77.
   PubMed Web of Science ®Google Scholar
• Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588. doi:10.3389/fimmu.2015.00588.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–875. doi:10.1038/nrc3380.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111. doi:10.1038/nri.2016.107.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461. doi:10.3389/fimmu.2014.00461.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291–295. doi:10.1126/science.1183021.
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085–2088. doi:10.1126/science.282.5396.2085.
   PubMed Web of Science ®Google Scholar
• Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol. 2000;165:618–622. doi:10.4049/jimmunol.165.2.618.
   PubMed Web of Science ®Google Scholar
• Lippitz BE, Harris RA. A translational concept of immuno-radiobiology. Radiother Oncol. 2019;140:116–124. doi:10.1016/j.radonc.2019.06.001.
   PubMed Web of Science ®Google Scholar
• Bryant CE, Spring DR, Gangloff M, Gay NJ. The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol. 2010;8:8–14. doi:10.1038/nrmicro2266.
   PubMed Web of Science ®Google Scholar
• Haas T, Metzger J, Schmitz F, Heit A, Müller T, Latz E, Wagner H. The DNA sugar backbone 2ʹ deoxyribose determines toll-like receptor 9 activation. Immunity. 2008;28:315–323. doi:10.1016/j.immuni.2008.01.013.
   PubMed Web of Science ®Google Scholar
• Humbert M, Hugues S. Warming up the tumor microenvironment in order to enhance immunogenicity. Oncoimmunology. 2019;8:e1510710. doi:10.1080/2162402X.2018.1510710.
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471–484. doi:10.1038/nrd2059.
   PubMed Web of Science ®Google Scholar
• Roers A, Hiller B, Hornung V. Recognition of endogenous nucleic acids by the innate immune system. Immunity. 2016;44:739–754. doi:10.1016/j.immuni.2016.04.002.
   PubMed Web of Science ®Google Scholar
• Schlee M, Hartmann G. Discriminating self from non-self in nucleic acid sensing. Nat Rev Immunol. 2016;16:566–580. doi:10.1038/nri.2016.78.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Kawai T. Discrimination between self and non-self-nucleic acids by the innate immune system. Int Rev Cell Mol Biol. 2019;344:1–30. doi:10.1016/bs.ircmb.2018.08.004.
   PubMed Web of Science ®Google Scholar
• Paludan SR, Reinert LS, Hornung V. DNA-stimulated cell death: implications for host defence, inflammatory diseases and cancer. Nat Rev Immunol. 2019;19:141–153. doi:10.1038/s41577-018-0117-0.
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. 2013;13:453–460. doi:10.1038/nri3446.
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353–364. doi:10.1038/nri2079.
   PubMed Web of Science ®Google Scholar
• Farahnak S, Chronopoulos J, Martin JG. Nucleic acid sensing in allergic disorders. Int Rev Cell Mol Biol. 2019;345:1–33. doi:10.1016/bs.ircmb.2018.11.001.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2013;2:e25771. doi:10.4161/onci.25771.
   PubMed Web of Science ®Google Scholar
• Kim YS, Park HJ, Park JH, Hong EJ, Jang G-Y, Jung ID, Han HD, Lee S-H, Vo M-C, Lee -J-J, et al. A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells. Oncoimmunology. 2018;7:e1472187. doi:10.1080/2162402X.2018.1472187.
   PubMed Web of Science ®Google Scholar
• Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine. 2007;25(Suppl 2):B72–88. doi:10.1016/j.vaccine.2007.06.043.
   PubMed Web of Science ®Google Scholar
• Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide-based vaccines in anticancer therapy. Oncoimmunology. 2018;7:e1511506. doi:10.1080/2162402X.2018.1511506.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol. 2011;8:551–561. doi:10.1038/nrclinonc.2011.72.
   PubMed Web of Science ®Google Scholar
• Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L. Trial watch: DNA-based vaccines for oncological indications. Oncoimmunology. 2017;6:e1398878. doi:10.1080/2162402X.2017.1398878.
   PubMed Web of Science ®Google Scholar
• Hoffman ES, Smith RE, Renaud RC Jr. From the analyst’s couch: TLR-targeted therapeutics. Nat Rev Drug Discov. 2005;4:879–880. doi:10.1038/nrd1880.
   PubMed Web of Science ®Google Scholar
• Tyring S. Imiquimod applied topically: A novel immune response modifier. Skin Therapy Lett. 2001;6:1–4.
   Google Scholar
• Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM. Coordinated activation of toll-like receptor8 (TLR8) and NLRP3 by the TLR8 agonist, VTX-2337, ignites tumoricidal natural killer cell activity. PloS One. 2016;11:e0148764. doi:10.1371/journal.pone.0148764.
   PubMed Web of Science ®Google Scholar
• Killock D. Haematological cancer: resiquimod-a topical CTCL therapy. Nat Rev Clin Oncol. 2015;12:563. doi:10.1038/nrclinonc.2015.142.
   PubMedGoogle Scholar
• Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176:157–164. doi:10.4049/jimmunol.176.1.157.
   PubMed Web of Science ®Google Scholar
• Bialojan A, Sohl J, Rausch J, Aranda Lopez P, Denny M, Langguth P, Hartmann A-K, Yagita H, Probst HC, Schild H, et al. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice. Eur J Immunol. 2019;49:2083–2094. doi:10.1002/eji.201848039.
   PubMed Web of Science ®Google Scholar
• Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, Birmachu W. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol. 2008;9:39. doi:10.1186/1471-2172-9-39.
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Cooley S, DeFor T, Weisdorf DJ, Panoskaltsis-Mortari A, Chen W, Blazar BR, Miller JS. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. Am J Hematol. 2012;87:953–956. doi:10.1002/ajh.23280.
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res. 2007;13:7119–7125. doi:10.1158/1078-0432.CCR-07-1443.
   PubMed Web of Science ®Google Scholar
• Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, Colman P, Kumar V, Cheng JB, Wright K, et al. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011;89:821–829. doi:10.1038/clpt.2011.60.
   PubMed Web of Science ®Google Scholar
• Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res. 2008;28:253–263. doi:10.1089/jir.2007.0097.
   PubMed Web of Science ®Google Scholar
• Astry C, Birmachu W, Harrison LI, Meng TC. Cutaneous pharmacodynamics of a toll-like receptor 7 agonist, 852A, in humans. J Clin Pharmacol. 2008;48:755–762. doi:10.1177/0091270008314466.
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Becker JC, Grob -J-J, Schadendorf D, Tebbs V, Skalsky J, Kaehler KC, Moosbauer S, Clark R, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res. 2008;14:856–864. doi:10.1158/1078-0432.CCR-07-1938.
   PubMed Web of Science ®Google Scholar
• Harrison LI, Astry C, Kumar S, Yunis C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol. 2007;47:962–969. doi:10.1177/0091270007303766.
   PubMed Web of Science ®Google Scholar
• Bryden SR, Pingen M, Lefteri DA, Miltenburg J, Delang L, Jacobs S, Abdelnabi R, Neyts J, Pondeville E, Major J, et al. Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site. Sci Transl Med. 2020;12:eaax2421. doi:10.1126/scitranslmed.aax2421.
   PubMed Web of Science ®Google Scholar
• Cromarty R, Sigal A, Liebenberg LJP, McKinnon LR, Abdool Karim SS, Passmore JAS, Archary D. Diminished HIV infection of target CD4+ T cells in a toll-like receptor 4 stimulated in vitro model. Front Immunol. 2019;10:1705. doi:10.3389/fimmu.2019.01705.
   PubMed Web of Science ®Google Scholar
• LaRue H, Ayari C, Bergeron A, Fradet Y. Toll-like receptors in urothelial cells–targets for cancer immunotherapy. Nat Rev Urol. 2013;10:537–545. doi:10.1038/nrurol.2013.153.
   PubMed Web of Science ®Google Scholar
• Lu R, Groer C, Kleindl PA, Moulder KR, Huang A, Hunt JR, Cai S, Aires DJ, Berkland C, Forrest ML. Formulation and preclinical evaluation of a toll-likereceptor 7/8 agonist as an anti-tumoral immunomodulator. J Control Release. 2019;306:165-176. doi:10.1016/j.jconrel.2019.06.003 306.
   Google Scholar
• Balan S, Saxena M, Bhardwaj N. Dendritic cell subsets and locations. Int Rev Cell Mol Biol. 2019;348:1–68. doi:10.1016/bs.ircmb.2019.07.004.
   PubMed Web of Science ®Google Scholar
• Ryan AT, Pulukuri AJ, Davaritouchaee M, Abbasi A, Hendricksen AT, Opp LK, Burt AJ, Nielsen AE, Mancini RJ. Comparing the immunogenicity of glycosidase-directed resiquimod prodrugs mediated by cancer cell metabolism. Acta Pharmacol Sin. 2020;41:995–1004. doi:10.1038/s41401-020-0432-4.
   PubMed Web of Science ®Google Scholar
• Lu Q, Qi S, Li P, Yang L, Yang S, Wang Y, Cheng Y, Song Y, Wang S, Tan F, et al. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy. J Mater Chem B. 2019;7:2499–2511. doi:10.1039/c9tb00089e.
   PubMed Web of Science ®Google Scholar
• Rao S, Gharib K, Han A. Cancer immunosurveillance by T cells. Int Rev Cell Mol Biol. 2019;342:149–173. doi:10.1016/bs.ircmb.2018.08.001.
   PubMed Web of Science ®Google Scholar
• Ota Y, Otsubo T, Goto M, Matsuki Y. Abstract 4078: enhanced anti-tumor activity through a combination of intravenous injectable TLR7 agonist, DSP-0509 and immune checkpoint inhibitors. Cancer Res. 2019;79:4078. doi:10.1158/1538-7445.am2019-4078.
   Web of Science ®Google Scholar
• Ackerman SE, Gonzalez JC, Gregorio JD, Paik JC, Hartmann FJ, Kenkel JA, Lee A, Luo A, Pearson CI, Nguyen ML, et al. Abstract 1559: TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models. Cancer Res. 2019;79:1559. doi:10.1158/1538-7445.am2019-1559.
   Google Scholar
• Wiedemann GM, Jacobi SJ, Chaloupka M, Krächan A, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, et al. A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. Oncoimmunology. 2016;5:e1189051. doi:10.1080/2162402X.2016.1189051.
   PubMed Web of Science ®Google Scholar
• de Oliveira ECV, da Motta VRV, Pantoja PC, Ilha CSDO, Magalhães RF, Galadari H, Leonardi GR. Actinic keratosis - review for clinical practice. Int J Dermatol. 2019;58:400–407. doi:10.1111/ijd.14147.
   PubMed Web of Science ®Google Scholar
• Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, et al. Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN. Clin Cancer Res. 2017;23:2442–2450. doi:10.1158/1078-0432.CCR-16-1934.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, et al. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the active8 randomized clinical trial. JAMA oncol. 2018;4:1583–1588. doi:10.1001/jamaoncol.2018.1888.
   PubMed Web of Science ®Google Scholar
• Maekawa H, Inoue T, Ouchi H, Jao T-M, Inoue R, Nishi H, Fujii R, Ishidate F, Tanaka T, Tanaka Y, et al. Mitochondrial damage causes inflammation via cGAS-STING signaling in acute kidney injury. Cell Rep. 2019;29:1261–1273 e1266. doi:10.1016/j.celrep.2019.09.050.
   PubMed Web of Science ®Google Scholar
• Grabosch S, Bulatovic M, Zeng F, Ma T, Zhang L, Ross M, Brozick J, Fang Y, Tseng G, Kim E, et al. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene. 2019;38:2380–2393. doi:10.1038/s41388-018-0581-9.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J clin oncol. 2005;23:4602–4608. doi:10.1200/JCO.2005.07.757.
   PubMed Web of Science ®Google Scholar
• Yuh BE, Ruel N, Wilson TG, Vogelzang N, Pal SK. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol. 2013;189:1682–1686. doi:10.1016/j.juro.2012.10.120.
   PubMed Web of Science ®Google Scholar
• Obrist F, Michels J, Durand S, Chery A, Pol J, Levesque S, Joseph A, Astesana V, Pietrocola F, Wu GS, et al. Metabolic vulnerability of cisplatin-resistant cancers. Embo J. 2018;37. doi:10.15252/embj.201798597.
   PubMed Web of Science ®Google Scholar
• Psyrri A, Burtness B. Targeted therapies: molecular selection for ‘smart’ study design in lung cancer. Nat Rev Clin Oncol. 2010;7:621–622. doi:10.1038/nrclinonc.2010.156.
   PubMed Web of Science ®Google Scholar
• de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007;67:6253–6262. doi:10.1158/0008-5472.CAN-07-0538.
   PubMed Web of Science ®Google Scholar
• Kansy BA, Shayan G, Jie H-B, Gibson SP, Lei YL, Brandau S, Lang S, Schmitt NC, Ding F, Lin Y, et al. T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. Oncoimmunology. 2018;7:e1494112. doi:10.1080/2162402X.2018.1494112.
   PubMed Web of Science ®Google Scholar
• Savinskii GA, Khudaibergenov RU, Mansurov BM. Various structural and functional mechanisms of development of peptic ulcers after vagotomy. Klin Khir. 1989;8:13–15.
   PubMedGoogle Scholar
• Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner J-E, Fend L, Bell JC, Mossman KL, et al. Trial Watch: oncolytic viro-immunotherapy of hematologic and solid tumors. Oncoimmunology. 2018;7:e1503032. doi:10.1080/2162402X.2018.1503032.
   PubMed Web of Science ®Google Scholar
• Brown CE, Mackall CL. CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 2019;19:73–74. doi:10.1038/s41577-018-0119-y.
   PubMed Web of Science ®Google Scholar
• Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185–199. doi:10.1038/s41573-019-0051-2.
   PubMed Web of Science ®Google Scholar
• De Santis R. Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. mAbs. 2020;12:1725346. doi:10.1080/19420862.2020.1725346.
   PubMed Web of Science ®Google Scholar
• Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33–48. doi:10.1038/s41571-019-0268-3.
   PubMed Web of Science ®Google Scholar
• Mohan N, Hosain S, Zhao J, Shen Y, Luo X, Jiang J, Endo Y, Wu WJ. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells. Oncoimmunology. 2019;8:e1624128. doi:10.1080/2162402X.2019.1624128.
   PubMed Web of Science ®Google Scholar
• Nie W, Qian J, Xu M-D, Gu K, Qian -F-F, Hu M-J, Lu J, Gan L, Zhang X-Y, Cao S-H, et al. A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab. Oncoimmunology. 2020;9:1731072. doi:10.1080/2162402X.2020.1731072.
   PubMed Web of Science ®Google Scholar
• Patinote C, Karroum NB, Moarbess G, Cirnat N, Kassab I, Bonnet P-A, Deleuze-Masquéfa C. Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes. Eur J Med Chem. 2020;193:112238. doi:10.1016/j.ejmech.2020.112238.
   PubMed Web of Science ®Google Scholar
• Brown RA, Herzig RH, Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Lowder JN, Harden EA, Hande KR, Herzig GP, et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood. 1990;76:473–479. doi:10.1182/blood.V76.3.473.473.
   PubMed Web of Science ®Google Scholar
• Sirachainan N, Pakakasama S, Anurathapan U, Hansasuta A, Dhanachai M, Khongkhatithum C, Jinawath A, Mahachoklertwattana P, Hongeng S. Outcome of newly diagnosed high risk medulloblastoma treated with carboplatin, vincristine, cyclophosphamide and etoposide. J clin neurosci. 2018;56:139–142. doi:10.1016/j.jocn.2018.06.028.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Pembrolizumab: living up to expectations. Blood. 2019;134:1114–1115. doi:10.1182/blood.2019002417.
   PubMed Web of Science ®Google Scholar
• Kuryk L, Moller AW, Jaderberg M. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2019;8:e1532763. doi:10.1080/2162402X.2018.1532763.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-an exclamation sign with a question mark. Oncoimmunology. 2015;4:e1058037. doi:10.1080/2162402X.2015.1058037.
   PubMed Web of Science ®Google Scholar
• Naing A, Gainor JF, Gelderblom H, Forde PM, Butler MO, Lin -C-C, Sharma S, Ochoa de Olza M, Varga A, Taylor M, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer. 2020;8(8):e000530. doi:10.1136/jitc-2020-000530.
   PubMedGoogle Scholar
• Ghanem S, Valecha GK, Hossri S, Ibrahim U, Atallah JP. Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm. Expert Opin Investig Drugs. 2017;26(1317–1319):1317–1319. doi:10.1080/13543784.2017.1395019.
   PubMedGoogle Scholar
• Weber MM, Fottner C. Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia. Oncol Res Treat. 2018;41:306–312. doi:10.1159/000488996.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. mAbs. 2020;12:1703531. doi:10.1080/19420862.2019.1703531.
   PubMed Web of Science ®Google Scholar
• Diab A, Marcondes M, Tagliaferri MA, Hoch U, Zhang J, Rubas W, Kivimae S, Zalevsky J, Conley1 AP, Borazanci E, et al. REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies. Ann Oncol. 2018;29:viii146–viii147. doi:10.1093/annonc/mdy279.433.
   Web of Science ®Google Scholar
• Sharma M, Khong H, Fa’ak F, Bentebibel S-E, Janssen LME, Chesson BC, Creasy CA, Forget M-A, Kahn LMS, Pazdrak B, et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020;11:661. doi:10.1038/s41467-020-14471-1.
   PubMed Web of Science ®Google Scholar
• Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS, Casalini JR, Thirstrup DJ, You S, et al. A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor. Sci Transl Med. 2015;7:284ra258. doi:10.1126/scitranslmed.aaa7489.
   Web of Science ®Google Scholar
• Frazier JP, Bertout JA, Kerwin WS, Moreno-Gonzalez A, Casalini JR, Grenley MO, Beirne E, Watts KL, Keener A, Thirstrup DJ, et al. Multidrug analyses in patients distinguish efficacious cancer agents based on both tumor cell killing and immunomodulation. Cancer Res. 2017;77:2869–2880. doi:10.1158/0008-5472.CAN-17-0084.
   PubMed Web of Science ®Google Scholar
• Dey J, Kerwin WS, Grenley MO, Casalini JR, Tretyak I, Ditzler SH, Thirstrup DJ, Frazier JP, Pierce DW, Carleton M, et al. A platform for rapid, quantitative assessment of multiple drug combinations simultaneously in solid tumors in vivo. PloS One. 2016;11:e0158617. doi:10.1371/journal.pone.0158617.
   PubMed Web of Science ®Google Scholar
• Moreno-Gonzalez A, Olson JM, Klinghoffer RA. Predicting responses to chemotherapy in the context that matters - the patient. Mol Cell Oncol. 2016;3:e1057315. doi:10.1080/23723556.2015.1057315.
   PubMed Web of Science ®Google Scholar
• Syed YY. Anlotinib: first global approval. Drugs. 2018;78:1057–1062. doi:10.1007/s40265-018-0939-x.
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA oncol. 2018;4:1569–1575. doi:10.1001/jamaoncol.2018.3039.
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, Lu Y, Shi Y, Wang Z, Jiang L, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118:654–661. doi:10.1038/bjc.2017.478.
   PubMed Web of Science ®Google Scholar
• Kobold S, Wiedemann G, Rothenfusser S, Endres S. Modes of action of TLR7 agonists in cancer therapy. Immunotherapy. 2014;6:1085–1095. doi:10.2217/imt.14.75.
   PubMed Web of Science ®Google Scholar
• Sautes-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, Dieu-Nosjean M-C. Tumor microenvironment is multifaceted. Cancer Metastasis Rev. 2011;30:13–25. doi:10.1007/s10555-011-9279-y.
   PubMed Web of Science ®Google Scholar
• Leclerc M, Mezquita L, Guillebot De Nerville G, Tihy I, Malenica I, Chouaib S, Mami-Chouaib F. Recent advances in lung cancer immunotherapy: input of T-CELL epitopes associated with impaired peptide processing. Front Immunol. 2019;10:1505. doi:10.3389/fimmu.2019.01505.
   PubMed Web of Science ®Google Scholar
• Gravett AM, Trautwein N, Stevanovic S, Dalgleish AG, Copier J. Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells. Oncoimmunology. 2018;7:e1438107. doi:10.1080/2162402X.2018.1438107.
   PubMed Web of Science ®Google Scholar
• Farhad M, Rolig AS, Redmond WL. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology. 2018;7:e1434467. doi:10.1080/2162402X.2018.1434467.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151–167. doi:10.1038/s41571-018-0142-8.
   PubMed Web of Science ®Google Scholar
• Martinek J, Wu TC, Cadena D, Banchereau J, Palucka K. Interplay between dendritic cells and cancer cells. Int Rev Cell Mol Biol. 2019;348:179–215. doi:10.1016/bs.ircmb.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10:127–140. doi:10.1038/nrd3264.
   PubMed Web of Science ®Google Scholar
• Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol. 2006;6:196–204. doi:10.1038/nri1787.
   PubMed Web of Science ®Google Scholar